cftr corrector 2

CFTR corrector 2 (FDL169) is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.

CFTR corrector 12 is a CFTR corrector that rescues all mutant proteins except M760R ABCA3, and can be used to study cystic fibrosis.

CFTR corrector 4 is a potent and orally available transmembrane conductance regulator (CFTR) for cystic fibrosis and is a potent (R,R) type active enantiomer. CFTR corrector 4 increases CFTR levels on the cell surface and is a potential compound for the study of cystic fibrosis.

CFTR corrector 8 is a highly effective modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). This compound is specifically designed for utilization in research related to cystic fibrosis, a genetic disorder primarily affecting the lungs and digestive system [1].

CFTR Corrector 9, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, is employed in the research of cystic fibrosis (CF) and related CFTR-associated disorders [1].

CFTR corrector 6 is a highly effective CFTR potentiator utilized in research on cystic fibrosis (CF) and related CFTR-associated disorders[1]. This potent compound exhibits potentiation activity on the Cystic Fibrosis Transmembrane conductance Regulator (CFTR), rendering it beneficial for investigations in CF and other associated conditions.

GLPG2737 is a strong CFTR type 2 corrector that can be combined with a type 1 co-corrector for cystic fibrosis research [1].